Showing results (131-140 of 148) with videos related to
Sort By:
Pageof 15
BMJ (Clinical Research Ed.)|October 18, 2008
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial diseaseJill Belch, Angus MacCuish, Iain Campbell, et al.Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|September 30, 2006
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPSOlga A Iakoubova, Carmen H Tong, Anand P Chokkalingam, et al.Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.Journal of the American Geriatrics Society|November 6, 2007
Association between apolipoprotein E4 and cognitive decline in elderly adultsChris J Packard, Rudi G J Westendorp, David J Stott, et al.Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.Cell|December 4, 2020
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and PathogenicityErik Volz, Verity Hill, John T McCrone, et al.Pageof 15